Apolipoprotein B and AI distributions in the United States, 1988-1991: Results of the National Health and Nutrition Examination Survey III (NHANES III)

Clinical Chemistry

Volumn 43, Issue 12, 1997, Pages 2364-2378

  Bachorik, Paul S ^a,c   Lovejoy, Kathleen L ^a   Carroll, Margaret D ^b   Johnson, Clifford L ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; ETHNIC GROUP; FEMALE; HEALTH SURVEY; HUMAN; IMMUNODIFFUSION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; UNITED STATES;

PIERINAE;

EID: 0031438039     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.12.2364     Document Type: Article

References (70)

1. Scanu AM, Byrne RE, Mihovilovic M. Functional roles of plasma high density lipoproteins. CRC Crit Rev Biochem 1982;13:109-40.
2. Norum KR, Gjone E, Glomset JA. Familial lecithin:cholesterol acyl transferase deficiency, including fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease, 6th ed. New York: McGraw-Hill, 1989:1181-94.
3. Johnson WL, Bamberger MJ, Latta RA, Rapp PE, Phillips MC, Rothblatt GH. The bidirectional flux of cholesterol between cells and lipoproteins. J Biol Chem 1986;261:5766-76.
4. Hokland BM, Slotte JP, Bierman EL, Oram JF. Cyclic AMP stimulates efflux of intracellular sterol from cholesterol loaded cells. J Biol Chem 1993;268:25343-9.
5. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease, 6th ed. New York: McGraw-Hill, 1989:1215-50.
6. Heiss G, Tyroler HA. Are apolipoproteins useful for evaluating ischemic heart disease? A brief overview of the literature. In: Lippel K, ed. Proceedings of the workshop on apolipoprotein quantification. Bethesda. MD: NIH Publication No. 83-1266, 1983:7-24.
7. Bachorik PS, Kwiterovich PO. Apolipoprotein measurements in clinical biochemistry and their utility vis-a-vis conventional assays. Clin Chim Acta 1988;178:1-34.
8. Sewdarsen M, Desai RK, Vythilingum S, Shah N, Rajput MC. Serum lipoproteins and apolipoproteins in young normocholesterolaemic, non-diabetic Indian men with myocardial infarction. Postgrad Med J 1991;67:159-64.
9. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
10. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I, B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990;150:1629-33.
11. Ford ES, Cooper RS, Simmons B, Castaner A. Serum lipids, lipoproteins and apolipoproteins in black patients with angiographically defined coronary artery disease. J Clin Epidemol 1990;43:425-32.
12. Kwiterovich PO, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992;69:1015-21.
13. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992;12:701-7.
14. Kostner GM. Apolipoproteins and lipoproteins of human plasma; significance in health and in disease. Adv Lipid Res 1983;20:1-43.
15. Sniderman AD, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO. Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density lipoproteins). Proc Natl Acad Sci U S A 1980;77:604-8.
16. Sniderman AD, Teng B, Jerry M. Determination of B protein of low density lipoprotein directly in plasma. J Lipid Res 1975;16:465-7.
17. Fruchart JC, Parra H, Cachera C, Clavey V, Bertrand M. Lipoproteins, apolipoproteins and coronary artery disease. Ric Clin Lab 1982;12:101-6.
18. Reisen WF, Mordasini R, Salzmann C, Theler A, Gurtner HP. Apolipoproteins and lipids as discriminators of severity of coronary heart disease. Arteriosclerosis 1980;37:157-62.
19. Whayne TF, Alaupovic P, Curry MD, Lee ET, Anderson PS, Schecter E. Plasma apolipoprotein B and VLDL-, LDL- and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography. Atherosclerosis 1981; 39:411-24.
20. Kozma L, Fodor J, Chockalingam A, Sussex B. LDL molecular size as risk factor in coronary artery disease. Acta Med Hung 1992-3;49:67-75.
21. Beigel Y, George J, Leibovici L, Mattityahu A, Sclarovsky S, Blieden L. Coronary risk factors in children of parents with premature coronary artery disease. Acta Paediatr 1993;82:162-5.
22. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-l-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991;32:383-94.
23. Harnsten A, Walldius G, Dahlen G, Johansson B. DeFaire V. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986;59:223-35.
24. Schmidt SB, Wasserman AG, Meusing RA, Schlesselman SE, LaRosa JC, Ross AM. Lipoprotein and apolipoprotein levels in angiographically defined coronary atherosclerosis. Am J Cardiol 1985;55:1459-62.
25. Lehtonen A, Mamiemi J, Inberg M, Maatela J, Alanen E, Niittymaki K. Levels of serum lipids, apolipoproteins A-I and B and pseudocholinesterase activity and their discriminative values in patients with coronary bypass operation. Atherosclerosis 1986;59:215-21.
26. Drexel H, Amann FW, Rentsch K. Neuenschwander C, Luethy A, Kahn SI, Follath F. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992;70:436-40.
27. 3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation 1992;85:22-9.
28. Kukita H, Hiwada K, Kokubu T. Serum apolipoprotein AI, AII and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis 1984;51:261-7.
29. Maciejko JT, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983;309:385-9.
30. DeBacker G, Rosseneau M, Deslypere JP. Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis 1982;42:197-203.
31. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PWF. Effects of age, gender and menopausal status on plasma low density lipoprotein cnolesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994;35:779-92.
32. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994;343:75-9.
33. Sigurdssoh G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992;69:1251-4.
34. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard P-M, Dagenais GR, Despres J-P. Apolipoprotein A-I, B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273-8.
35. Coleman MP, Key TJA, Wang DY, Hermon C, Fentiman IS, Allen DS, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992; 92:177-85.
36. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). J Clin Invest 1994;24:444-53.
37. Salonen JT, Salonen R, Penttila I, Herranen J, Jauhiainen M, Kantola M, et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 1985;56:226-31.
38. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:507-14.
39. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaeffer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:515-23.
40. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital and Health Statistics, series 1, PHS Publication 94-1308, 1994.
41. Bachorik PS, Lovejoy KL, Carroll MD, Johnsen CL, Albers JJ, Marcovina SM. Measurement of apolipoproteins AI and B in the National Health and Nutrition Examination Survey. Clin Chem 1994;40:1915-20.
42. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-8.
43. 3. Clin Chem 1984;30:839-42.
44. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
45. Shah BV, Barnwell BG, Hunt PN, Nileen P, LaVage LM. SUDAAN, Users manual, release 5.50. Research Triangle Park, NC: Research Triangle Institute, Inc., 1991.
46. SAS/Stat Users Guide, version 6, 3rd ed. Cary, NC: SAS Institute, Inc., 1990.
47. National Cholesterol Education Program. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
48. National Cholesterol Education Program Working Group on Lipoprotein Measurement. Recommendations on lipoprotein measurement. NIH Publication 95-3044, Bethesda, MD: National Heart, Lung, and Blood Institute, NIH, Sept 1995.
49. The Lipid Research Clinics population studies data book, Vol. 1. The prevalence study. NIH Publication 80-1527, Bethesda, MD: US Department of Health and Human Services, July 1980.
50. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, et al. Prevalence of high blood cholesterol among US adults. JAMA 1993;269:3009-14.
51. Albers JJ, Wahl PW, Cabana VG, Hazzard WR, Hoover JJ. Quantitation of apolipoprotein Al of human plasma high density lipoprotein. Metabolism 1976;25:633-44.
52. Albers JJ, Cabana VG, Hazzard W. Immunoassay of human plasma apolipoprotein B. Metabolism 1975;24:1339-51.
53. Noma A, Hata Y, Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values and age- and sex-related differences. Clin Chim Acta 1991;199:147-57.
54. Vermaak WJH, Kotze JP, van der Merwe AM, Becker PJ, Ubbink JB, Barnard HC, et al. Epidemiological reference ranges for low-density lipoprotein cholesterol and apolipoprotein B for identifica tion of increased risk for ischaemic heart disease. S Afr Med J 1991;79:367-71.
55. Kinlay S, Dobson AJ, Heller RF, Dickeson JE, Ryan S. Lipid and apolipoprotein levels in an Australian community. Med J Aust 1991;154:170-5.
56. Sarihyan S, Lal Wahi P, Kumar Ganguly N. Distribution of apolipoproteins in normal individuals of various age groups. Jpn Heart J 1990;31:477-81.
57. Kottke BA, Moll PP, Michels W, Weidman WH. Levels of lipids, lipoproteins, and apolipoproteins in a defined population. Mayo Clin Proc 1991;66:1198-208.
58. Donahue RP, Jacobs DR, Sidney S, Wagenknecht LE, Albers JJ, Hulley SB. Distribution of lipoproteins and apolipoproteins in young adults. The CARDIA Study Arterioscler 1989;9:656-64.
59. Wardlaw GM, Snook JT, Lin M-C, Puangco MA, Kwon JS. Serum lipid and apolipoprotein concentrations in healthy men on diets enriched in either canola oil or safflower oil. Am J Clin Nutr 1991;54:104-10.
60. Zunic G, Jelic-Ivanovic Z, Spasic S, Stojilkovic A, Majkic-Singh N. Reference values for apolipoproteins A-I and B in healthy subjects by age. Clin Chem 1992;38:566-9.
61. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis 1990;10: 668-71.
62. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W, for the ARIC Study Group. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb 1993;13:1139-58.
63. Srinivasan SR, Berenson GS. Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: the Bogalusa heart study. Clin Chem 1995;41:159-64.
64. Miller JP, Mao SJT, Patsch JR, Gotto AM. The measurement of apolipoprotein A-I in human plasma by electroimmunoassay. J Lipid Res 1980;21:775-80.
65. Albers JJ, Cheung MC, Wahl PW. Effect of storage on the measurement of apolipoproteins AI and AII by radial immunodiffusion. J Lipid Res 1980;21:874-8.
66. Havekes L, Hemmink J, deWit E. Low-density-lipoprotein apoprotein B in plasma as measured by radial immunodiffusion and rocket electrophoresis. Clin Chem 1981;27:1829-33.
67. Karlin JB, Juhn DG, Scanu AM, Rubenstein AH. Measurement of serum apolipoprotein B by radioimmunoassay. Eur J Clin Invest 1978;8:19-26.
68. Durrington PN, Whicher ST, Warren C, Bolton CH, Harrog M. A comparison of methods for the immunoassay of serum apolipoprotein B in man. Clin Chim Acta 1976;71:95-108.
69. Kafonek S, Bachorik PS, Kwiterovich PO. Measurement of apolipoprotein B in plasma from hyperlipidemic subjects treated with cholestyramine or placebo: differential effects of storage at -70 °C. Clin Chem 1989;35:380-3.
70. Brown SA, Epps DF, Dunn JK, Sharrett AR, Patsch JR, Gotto AM, Patsch W. Effect of blood collection and processing on radioimmunoassay results for apolipoprotein B in plasma. Clin Chem 1990;36:1662-6.